Publication: Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients.
| dc.contributor.author | Ocio, Enrique M | |
| dc.contributor.author | Bringhen, Sara | |
| dc.contributor.author | Martinez-Lopez, Joaquin | |
| dc.contributor.author | San-Miguel, Jesus | |
| dc.contributor.author | Oliva, Stefania | |
| dc.contributor.author | Rodriguez-Otero, Paula | |
| dc.contributor.author | Le Roux, Nadia | |
| dc.contributor.author | Dong, Yvonne | |
| dc.contributor.author | Doroumian, Severine | |
| dc.contributor.author | Macé Sandrine | |
| dc.contributor.author | Mateos, Maria-Victoria | |
| dc.contributor.funder | Sanofi | |
| dc.date.accessioned | 2024-09-16T08:17:05Z | |
| dc.date.available | 2024-09-16T08:17:05Z | |
| dc.date.issued | 2023-02 | |
| dc.description.peerreviewed | Sí | es_ES |
| dc.description.sponsorship | This study was funded by Sanofi. | es_ES |
| dc.format.number | 2 | es_ES |
| dc.format.page | e829 | es_ES |
| dc.format.volume | 7 | es_ES |
| dc.identifier.citation | Hemasphere . 2023 ;7(2):e829. | es_ES |
| dc.identifier.doi | 10.1097/HS9.0000000000000829 | es_ES |
| dc.identifier.e-issn | 2572-9241 | es_ES |
| dc.identifier.journal | HemaSphere | es_ES |
| dc.identifier.pubmedID | 36751513 | es_ES |
| dc.identifier.uri | https://hdl.handle.net/20.500.12105/23106 | |
| dc.language.iso | eng | es_ES |
| dc.publisher | Wiley | |
| dc.relation.publisherversion | https://doi.org/10.1097/HS9.0000000000000829 | es_ES |
| dc.repisalud.institucion | CNIO | es_ES |
| dc.repisalud.orgCNIO | CNIO::Unidades técnicas::Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIO | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.title | Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients. | es_ES |
| dc.type | research article | es_ES |
| dc.type.hasVersion | VoR | es_ES |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 9b25aa8e-597b-43e0-90d0-6d3846974c12 | |
| relation.isAuthorOfPublication.latestForDiscovery | 9b25aa8e-597b-43e0-90d0-6d3846974c12 | |
| relation.isFunderOfPublication | c8cb3bed-d592-45b3-8cc2-397e6d588d95 | |
| relation.isFunderOfPublication.latestForDiscovery | c8cb3bed-d592-45b3-8cc2-397e6d588d95 | |
| relation.isPublisherOfPublication | d81e762a-95f7-4917-88a1-8004b3b8caa7 | |
| relation.isPublisherOfPublication.latestForDiscovery | d81e762a-95f7-4917-88a1-8004b3b8caa7 |


